Imatinib is a tyrosine kinase inhibitor that has undoubtedly saved and improved the quality of lives of many thousands of patients with chronic myeloid leukaemia (CML). It has become the treatment of choice for newly diagnosed patients in chronic phase, and a recent report suggests that modern drug treatment may produce superior results to allogeneic stem cell transplantation (SCT). 1 The imatinib-treated cohort within the International Randomized Study of Interferon and STI571 (IRIS) has provided valuable information on the longer term effects of imatinib treatment. On 400 mg daily, the overall survival at 5 years is 89%. 2 Furthermore, the IRIS data suggest that the rate of disease progression may decrease with time. However, these data are derived from a clinical trial, and it is therefore important to establish if these results can be reproduced in a more general CML population. Here we present the results of a populationbased study of CML treated with 400 mg daily imatinib in our health-care area.
In our area of the North West of England, the adjacent North Wales coastal strip and the Isle of Man (total population 2 million), all services for adults with haematological cancer are located at 12 hospitals. Molecular diagnosis of CML and monitoring for BCR-ABL transcripts are carried out at a single centre (RLUH) for all CML patients in this geographical area. We are therefore able to trace the clinical course of every CML patient in our area.
All patients aged 16 years or more with CML newly diagnosed between 1 January 2003 and 30 June 2006 are included in this study. Younger patients were excluded as imatinib usage in children is not universal, and earlier patients were excluded as the timing of imatinib approval in 2002 varied across our geographical area. Patients were included in the assessment of imatinib efficacy if they received imatinib 400 mg daily from original diagnosis (preceded only by up to 6 weeks of hydroxycarbamide).
Considerable effort was made to include all CML cases, first from the records at the molecular diagnostic centre and second through the specific enquiry of local haematologists. Local haematologists verified that each case had never received prior interferon-a or alternative chemotherapy.
Responses were defined conventionally: 3 complete haematological response (CHR) ¼ normalization of the blood count and resolution of splenomegaly; complete cytogenetic response (CCR) ¼ no Ph þ metaphases among at least 20 marrow metaphases or a BCR-ABL/ABL ratio of 1% or less, 4 which we have previously shown to be tightly correlated with cytogenetically defined CCR; major molecular response (MMR) ¼ a BCR-ABL/ABL ratio of 0.1% or less. Measurement of BCR-ABL transcripts was carried out as described earlier using quantitative real-time PCR. 4, 5 In some cases, serial cytogenetic data were not available and achievement of CCR is based on a BCR-ABL/ABL transcript ratio of below 1%; we have therefore used the term 'CCR equivalence' (CCRe) to encompass these cases.
Over the 42 months of the study, 88 new cases of CML were seen, giving an annual incidence of 1.2 cases per 100 000 population per annum. These comprised 41 men and 47 women, and their median age at diagnosis was 53.4 years (range 18.6-86.8 years). Of these, four presented in blast crisis and were treated with chemotherapy before imatinib and then SCT. Of the 84 presenting in chronic phase, 16 cases were not assessable for the effect of imatinib as they first received interferon-a (seven cases) or an elective SCT (one case); or because insufficient follow-up data were available (eight cases).
A flow diagram of patient outcome is given in Figure 1 . During the first 12 months of treatment, 3 of the 68 patients who received imatinib from original diagnosis progressed to blast crisis, of whom two died and one achieved a second chronic phase during which she underwent SCT. Two patients had Letters to the Editor serious side effects attributable to imatinib (one Stevens-Johnson syndrome, one hepatotoxicity) and were successfully treated with an alternative tyrosine kinase inhibitor. One further patient lost an initial CHR and proceeded to SCT. Six cases therefore failed imatinib before 12 months. Of the 62 cases that were assessable for response at 12 months, 28 had achieved CCRe. Twenty-three of these 28 cytogenetic responders (CCRe) were assessable at 18 months of imatinib treatment, and 22 remained in CCRe; the remaining case developed central nervous system blast crisis. Of the 34 cases who had not achieved CCRe at 12 months, eight patients achieved CCRe at 18 months.
Twelve of the original 68 imatinib-treated patients were unassessable at 18 months (three cases lost their CHR and proceeded to SCT, two died of disease progression and seven cases had not reached the 18-month assessment point). By 24 months, a total of six of the original 68 imatinib-treated patients had progressed to advanced phase (9%), and 10 further cases remained in chronic phase but had received SCT or switched to Table 1 CCRe response rate for all 88 patients and the 68 patients who received imatinib from initial diagnosis an alternative tyrosine kinase inhibitor, because of intolerance (three cases) or failure to achieve/maintain CCRe. The flow diagram for all imatinib-treated patients is given in Figure 1 . The overall CCRe rates were 41% (28 of 68 patients) at 12 months, 49% (30 of 61 assessable cases) at 18 months and 51% (28 of 55 assessable cases) at 24 months (Table 1) . MMR rates were 22% at 12 months, 26% at 18 months and 31% at 24 months.
Time (months)
Using recommended criteria, 3 at 24 months, 49% (27 of 55 assessable cases) had failed imatinib because of either progression to blast crisis (six cases; all fatal), failure to achieve/maintain CCRe (19 cases, of which four lost CHR as well) or intolerance (two cases). Fourteen of the 15 failures who remain in CHR and without disease progression have achieved and remain in CCRe at latest follow-up, following either SCT or an alternative tyrosine kinase inhibitor. Figure 2 gives the event-free survival rate according to Sokal score; no statistically significant difference is seen.
Despite several hundred publications on various clinical aspects of imatinib, there are, to our knowledge, only three series describing results in previously untreated patients. The IRIS trial demonstrated that after 5 years of imatinib therapy, the overall survival of patients was 89%, with 87% achieving a CCR. 2 In a separate study of 279 newly diagnosed patients presenting to the MD Anderson Hospital, 87% achieved a CCR, with an estimated 3-year survival rate of 96%. 6 In a recent report in abstract form on 207 consecutive patients referred to the Hammersmith Hospital in London, the 4-year progression-free survival was estimated at 90%, with 34 (16%) discontinuing imatinib while still in chronic phase. The cumulative incidence of CCR and MMR was 59 and 12% by 12 months, and 87 and 58% by 48 months, respectively. The cumulative incidence of loss of CCR at 48 months was 17%. 7 None of these three studies were population-based.
In contrast, our population-based study shows that, by using the recommended criteria, 3 at 24 months 49% (27 of 55 assessable cases) had failed or were intolerant of imatinib. The data suggest that caution is needed in extrapolating clinical trial data to the general CML population. Increasing data suggest that activating kinase mutations are important in chronic and acute hematologic malignancies. The prototypical example is the BCR-ABL kinase that is activated in chronic myelogenous leukemia and Philadelphia chromosome positive acute lymphoblastic leukemia (ALL), but activating kinase mutations have also been identified in chronic myelomonocytic leukemia, chronic eosinophilic leukemia and systemic mastocytosis. Circumstantial evidence suggests that gain-of-function tyrosine kinase alleles could also contribute to the pathogenesis of chronic lymphocytic leukemia (CLL). Microarray studies of gene expression differences between steadily progressive CLLs that lack somatic hypermutation of the immunoglobulin heavy chain variable gene region (IgVH unmutated) and more indolent IgVH-mutated CLLs have found that many of the differentially expressed genes are involved in B-cell receptor signaling, most notably the ZAP-70 tyrosine kinase. Other kinases found to be overexpressed in CLL by gene expression studies include BLK, JAK2, LYN, and NTRK3, although mutational analysis of these genes in CLL has been limited. The goal of this project was therefore to search
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